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 
Abstract— Hyperglycaemia is a common complication in the 
intensive care unit (ICU), and is associated with worsened 
outcomes. Model-based insulin therapy protocols have been 
shown to be safe and effective in intensive care. Such protocols 
rely on correct modeling of glucose-insulin dynamics. In 
particular, model-based control typically relies on insulin 
sensitivity (SI) metrics, which are heavily influenced by plasma 
insulin kinetics. Plasma insulin samples were taken as part of a 
sepsis study and compared to modeled plasma insulin. Samples 
were taken in septic patients at the onset of glycaemic control, 
and once the patient consistently met less than two of the SIRs 
criteria that help define sepsis. It was found that inter-patient 
insulin dynamics were more variable at the onset of insulin 
therapy, than in the later samples after sepsis abated. Overall, 
the model adequately captured crucial steady state dynamics. 
Transient dynamics in plasma insulin following a bolus were 
faster than modeled, indicating greater clearance of insulin 
than currently modeled. 
I. INTRODUCTION 
Stress-induced hyperglycaemia is a common complication in 
the intensive care unit (ICU), even in patients with no 
history of diabetes [1-3], and is associated with increased 
mortality and morbidity [1, 4-9]. Insulin therapy can be used 
to treat hyperglycaemia, but can result in hypoglycaemia, 
which is associated with increased mortality [10], and results 
from excessive intra- and inter- patient variability. STAR is 
a physiological model-based insulin therapy protocol that 
has proven safe and effective in intensive care [11, 12].  
Model-based protocols rely on the inherent accuracy and 
usability of their models [13]. Key aspects of a glucose-
insulin system compartment model, when used in control, 
are the plasma and peripheral insulin concentrations. Insulin 
mediates glucose uptake into body cells, where it is stored or 
used. Insulin is cleared via liver and kidney clearance, as 
well as diffusion to interstitial fluid and cellular degradation 
[14]. Within the STAR model-based framework, an insulin 
sensitivity parameter is used to describe the time varying and 
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patient-specific metabolic effect of insulin on insulin-
mediated glucose uptake [15]. Thus, accuracy of plasma 
insulin dynamics has a significant impact of identified 
parameters such as insulin sensitivity (SI), and, in turn, on 
the recommended dosing. 
In particular, insulin sensitivity is used alongside stochastic 
modelling methods to predict future changes in blood 
glucose for a given dose [11, 16]. Thus, reduction of error in 
modelled plasma insulin can reduce SI variability and 
further increase the accuracy and utility of the parameter for 
glycaemic control. This paper evaluates the accuracy of 
insulin system models for intravenous (IV) insulin 
administration. Plasma insulin blood samples from a study 
of sepsis were used to evaluate these models.  
II. PATIENTS AND METHODS 
A. Sepsis Study Patients 
19 patients enrolled in a prospective clinical trial studying 
sepsis at the Christchurch Hospital Intensive Care Unit 
(ICU) each had an additional two sets of blood samples 
assayed for insulin and C-peptide. Patients received insulin 
therapy (Actrapid, Actrapid, Novo Nordisk, Denmark) under 
the SPRINT protocol [17], a precursor to the STAR 
protocol.  Patients were included in the study if they met all 
of the following criteria:  
 Age ≥ 16 years  
 Expected survival ≥ 72hrs 
 Expected ICU length of stay ≥ 48hrs 
 Entry to the SPRINT glycaemic control protocol (2 
sequential BG measurements ≥ 8mmol/L) 
 Suspected sepsis or SIRS score ≥ 3 
Patient characteristics are in Table I. 
TABLE I. SUMMARY OF SEPSIS STUDY PATIENT 
CHARACTERISTICS. DATA ARE SHOW AS MEDIAN [IQR] WHERE 
APPROPRIATE. 
N 19 
Age (years) 68 [57-75] 
Gender (M/F) 10/9 
APACHE II score  22.0 [18.3-26.8] 
Confirmed Sepsis 79% 
Hospital mortality (L/D) (13/6) 
Diagnosed T2DM 3 
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Patients received treatment for suspected sepsis 
with antibiotics. No type 1 diabetic patients were 
included. This study was approved by the Upper 
South Regional Ethics Committee, New Zealand.  
One additional sepsis patient admitted to the ICU 
after pancreatoduodenectomy (Whipple 
procedure) was excluded from this analysis as 
this procedure involved removing a section of the 
pancreas and may thus have affected insulin 
secretion beyond model assumptions.  Two other 
patients each only had one set of blood samples 
assayed as one was discharged from the ICU 
within 48 hours and the other did not meet the 
criteria for the second set to be taken. 
Each patient had two sets of blood samples taken, 
where each set consisted of 4 separate samples. 
The first set of samples (Sample Set 1) was taken 
at the commencement of the SPRINT protocol 
[17]. The second set (Sample Set 2) was taken 
when the patient consistently met less than 2 of the SIRS 
criteria (Systemic Inflammatory Response Syndrome) [18].   
The  first  sample  of  each  set  was  taken  immediately  
prior  to  bolus  delivery  of insulin as required by SPRINT (t 
= -1 min). The remaining three samples were taken at t = 10, 
40, and 60 minutes. Plasma was separated from the blood 
samples and frozen for subsequent analysis.    
Insulin concentrations were determined using immunometric 
assays (Elecsys 2010, Roche Diagnostics, Germany).  The 
reported coefficients of variation (CVA) for the insulin 
assays were 3.8% [19, 20]. 
B.  ICING Model  
For this study, the clinically validated Intensive Control 
Insulin-Nutrition-Glucose (ICING) model of the glucose-
insulin system was used [11, 15] to describe blood glucose, 
G, plasma insulin, I, and peripheral insulin, Q, 
concentrations: 
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𝑢𝑒𝑛 = 𝑚𝑎𝑥 (16.67,
14 ∗ 𝐺
1 + 0.0147 ∗ 𝐺
− 41) (4) 
Where P and PN are glucose appearance from enteral and 
parenteral routes respectively. 𝑢𝑒𝑥 is insulin introduced via 
IV bolus or infusion, and 𝑢𝑒𝑛 is pancreatic insulin secretion. 
Further parameter descriptions and values can be found in 
Table 2. 
C. Analysis of model accuracy 
Model error was analyzed in terms of the difference between 
measured and modeled insulin (vertical error) and 
perpendicular error. Vertical error is defined: 
𝐸𝑣𝑒𝑟𝑡 = 𝐼𝑎𝑠𝑠𝑎𝑦 − 𝐼𝑚𝑜𝑑𝑒𝑙𝑙𝑒𝑑  (5) 
Perpendicular error is the smallest distance between a data 
point and the model, and better takes into account timing 
(horizontal) error in cases where the model gradient is very 
high. Perpendicular error is minimized a total least squares 
approach [21]. Perpendicular error is defined: 





Where tn is the assay time, and tn+i is the time corresponding 
to some nearby model solution. For each set of 4 samples the 
RMS vertical and perpendicular error was calculated. 
To test sensitivity of insulin dynamics to clearance 
parameter values nL, nK, nI and nC were multiplied by a 
constant, ξ, which was allowed to range between 0.1 and 3.0. 
The intention was to find the ξ which resulted in the best 
model fit with minimized perpendicular and vertical error.  
III. RESULTS AND DISCUSSION 
Measured sample results are shown in Table III. While 
plasma insulin was not significantly different (p=0.11), 
plasma C-peptide concentration was much higher across 
Sample set 1 (p<<0.001, Table III), indicating that insulin 
secretion was much higher in these samples, or clearance of 
C-peptide was lower but insulin clearance was not. This was 
also true when comparing C-peptide concentration across the 
first sample of each sample set (2225 [980-2735] vs. 799 
[478 – 1000] pmol/L, p=0.002), indicating that steady-state 
pre-insulin-bolus insulin secretion is higher when patients 
are septic.  
TABLE  II. ICING MODEL PARAMETER DESCRIPTION AND VALUES. 
 
Variable Description 
Value  and/or 
units 
𝑝𝐺  Endogenous glucose clearance 0.006 min
-1
 
𝑆𝐼  Insulin sensitivity* L/mU/min 
𝛼𝐺 Insulin-mediated glucose uptake saturation 1/65 L/mU 
𝐸𝐺𝑃𝑏  Basal endogenous glucose production 1.16 mmol/min 
𝐶𝑁𝑆 Central nervous system glucose uptake 0.3 mmol/min 
𝑉𝑔 Distribution volume for glucose 13.3 L 
𝑛𝐿 Liver clearance of insulin 0.158 min
-1
 
𝑛𝐾 Kidney clearance of insulin 0.054 min
-1 
𝑛𝐼 Plasma ↔ interstitial insulin diffusion 0.0075 min
-1
 
𝑛𝐶 Peripheral degradation of insulin 0.0075 min
-1
 
𝑥𝐿 First pass hepatic clearance of insulin 0.67 
𝛼𝐼 Saturation on liver clearance of insulin 1.7x10
-3
 L/mU 
𝑉𝐼 Distribution volume for insulin 4.0 L 
*Insulin sensitivity is fit on a time varying, per-patient basis from 
measured BG data. 
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Sample set 1 - 24.0 [10.4 – 52.7] 2050 [993 – 2770] 
Sample set 2 84 [77-142] 20.9 [7.9 – 42.9] 758[487 – 1052] 
All - 20.9 [8.6 – 51.4] 1270 [558 – 2345] 
Plasma insulin concentrations and model solution are shown 
in Figure I. It can be seen that in most cases the initial 
insulin clearance is faster than currently modeled. This result 
is also seen in Table II, where ξ>1 resulted in improved 
model fit across most of the samples. Across both initial and 
follow up sampling groups, the median [IQR] value of ξ that 
was required to optimize model fit was 2.1 [1.3 – 2.7], 
suggesting that generalized insulin clearance is twice as fast 
as the value originally modeled, and thus that one or more of 
the clearance dynamics is significantly faster than currently 
modeled.  
In the original formulation of ICING model parameters, Lin 
et al used a combination of known C-peptide dynamics,  and 
grid search over a likely physiological parameter range [15]. 
The grid search selected values such that the difference 
between modeled and measured BG was minimized. It is 
thus likely that, while these insulin clearance parameters are 
within a physiologically likely range, insulin dynamics may 
in reality be faster.  
Model error was higher (p≤0.06) in the first set of blood 
samples, corresponding to the onset of tight glycaemic 
control in a septic patient, reflecting the higher inter-patient 
variability seen in plasma insulin clearance at this stage in a 
patient’s infection state. Table III indicates that insulin was 
cleared faster at the time the first set of samples was taken 
(higher ξ).  C-peptide results also suggest higher insulin 
secretion in the septic sample cohort, reflecting relative 
insulin resistance. This result seems to indicate that insulin 
dynamics are disease state dependant in their value. 
The second set of samples were taken when a patient 
consistently met less than two of the SIRS criteria, reflecting 
improved patient condition. Lower model error in this set of 
samples indicates that in less ill patients insulin dynamics 
are more consistent between patients, and are thus more 
easily modeled. ξ was also lower, indicating that insulin was 
cleared more slowly than in the first sample sets. 
 Model error in general was higher in the first half hour 
following the insulin bolus, where plasma insulin was more 
dynamic. The vertical error is greater than the 3.8% error 
associated with the immunoassay procedure. However, the 
difference between vertical and perpendicular error is high, 
indicating that slight offsets in time result in significant 
differences in insulin concentration due to large gradients in 
the modeled trajectory around a bolus. In this situation, 
perpendicular error gives a more informative reference for 
model error, as timing offsets between model and samples in 
samples are clinical reality due to a number of factors, such 
as timing differences in sampling and therapy.  
In the case of the STAR protocol, the ability of the model to 
capture the steady state dynamics is more important than the 
ability to capture the first transient insulin peak following an 
IV insulin bolus. This priority occurs because, while 
transient plasma insulin contributes to initial BG drop, final 
BG at the end of an hour is more dependent on the steady 
state plasma insulin concentration. This final BG value is 
what drives the control protocol, and measured response 
based on infrequent BG measurements is more important 
than the transient trajectory in between those measurements.  
 
FIGURE I. ASSAY VALUES AND MODELED RESPONSE ACROSS 
ALL PATIENTS AND SAMPLING GROUPS. 








































Model 5th and 95th
Model 25th and 75th
Median modelled response
TABLE IV: MODEL FIT TO INSULIN ASSAY DATA FOR DIFFERENT INSULIN CLEARANCE PRAMTERS 













Sample set 1 202 [116.2 – 454.3] 24.8 [18.9 – 71.7] 2.4 [1.1 – 2.7] 158.6 [64.6 –318.9] 16.0 [11.7 – 31.2] 
Sample set 2 87.4 [101.1 -128.3] 18.6 [13.7 – 33.2] 1.8 [1.3 – 2.3] 62.1 [29.6 – 128.6] 11.3 [ 4.7 – 18.0] 
All 123.7 [89.2 – 234.7] 22.7 [15.4 – 37.9] 2.1 [1.3 – 2.7] 97.1 [43.5 – 192.5] 13.3 [9.3 – 19.8] 
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Blood samples were to be taken at 0, 10, 40, and 60 minutes 
after an IV insulin bolus, but in some cases clinical workload 
and/or repeated sampling requirements resulted in a delay. 
Figure I shows that this sampling regime is insufficient to 
capture the initial data peak. A sampling regime of 0, 5, 10, 
20 and 60 minutes would better capture initial insulin 
dynamics. 
In general, Figure I shows that the insulin kinetics of the 
ICING model fall within what might be clinically observed. 
Across most samples, insulin clearance was higher than 
currently modeled, and insulin clearance was highest at the 
onset of glycaemic control when the patients were most 
unwell. Inter- and intra- patient variability in the rate of 
insulin clearance (Table IV) reflects previously observed 
variability in human glucose-insulin physiology [22], and 
the need for adaptive control methods [23].  
These results suggest that the insulin clearances within the 
model should be made faster. However, the ICING model 
must be generalisable to all patient cohorts across the ICU, 
unless clear condition or patient specific differences can be 
consistently noted at the bedside. Further work over other 
ICU patient cohorts and underlying disease conditions is 
required to develop more condition and time dependant 
modeling of clearance parameters. Overall, crucial steady 
state plasma insulin levels following an IV insulin bolus are 
captured.  
IV. CONCLUSION 
Plasma insulin samples were taken in sepsis patients at 
glycaemic control onset, and once the patient met less than 2 
of the SIRs criteria, a median of 84 hours later. The ICING 
model’s insulin kinetic models were evaluated against these 
samples, and it was found that in general plasma insulin 
clearances were faster than currently modeled. Inter-patient 
variability was higher at the onset of glycaemic control. 
Model fitting error and insulin clearance was lower in the 
second set of samples. C-peptide concentration was higher in 
the first set of samples, with similar plasma insulin 
concentrations, suggesting that insulin secretion was higher 
when the patient was more ill, and relative insulin sensitivity 
was lower. These overall results suggest that insulin kinetics 
are condition dependant. Thus, it is critical to develop 
greater data sets and delineate the variation across common 
or particularly critical, such as sepsis, patient conditions. 
Capturing this variability in the insulin dynamics modeling 
will ensure that all other, already well-proven models remain 
fully generalisable. 
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